UY38228A - Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer - Google Patents

Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer

Info

Publication number
UY38228A
UY38228A UY38228A UY38228A UY38228A UY 38228 A UY38228 A UY 38228A UY 38228 A UY38228 A UY 38228A UY 38228 A UY38228 A UY 38228A UY 38228 A UY38228 A UY 38228A
Authority
UY
Uruguay
Prior art keywords
treatment
cancer
ring
triazolopyrimidine compounds
compounds
Prior art date
Application number
UY38228A
Other languages
English (en)
Spanish (es)
Inventor
Grant Kettle Jason
Kuan Tsuei Ting Attila
Mcgregor Lamont Gillian
David Buttar
Woolf Goldberg Frederick
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY38228A publication Critical patent/UY38228A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
UY38228A 2018-05-11 2019-05-10 Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer UY38228A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862670075P 2018-05-11 2018-05-11

Publications (1)

Publication Number Publication Date
UY38228A true UY38228A (es) 2019-10-31

Family

ID=66484070

Family Applications (1)

Application Number Title Priority Date Filing Date
UY38228A UY38228A (es) 2018-05-11 2019-05-10 Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer

Country Status (16)

Country Link
US (3) US11084827B2 (cg-RX-API-DMAC7.html)
EP (2) EP3790879B1 (cg-RX-API-DMAC7.html)
JP (1) JP7418353B2 (cg-RX-API-DMAC7.html)
KR (1) KR102863374B1 (cg-RX-API-DMAC7.html)
CN (3) CN115028637B (cg-RX-API-DMAC7.html)
AR (1) AR115384A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019264826B2 (cg-RX-API-DMAC7.html)
CA (1) CA3099579A1 (cg-RX-API-DMAC7.html)
DK (1) DK3790879T3 (cg-RX-API-DMAC7.html)
ES (1) ES2927244T3 (cg-RX-API-DMAC7.html)
MX (1) MX2020012058A (cg-RX-API-DMAC7.html)
PT (1) PT3790879T (cg-RX-API-DMAC7.html)
TW (1) TWI823932B (cg-RX-API-DMAC7.html)
UY (1) UY38228A (cg-RX-API-DMAC7.html)
WO (1) WO2019215316A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202006971B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI823932B (zh) * 2018-05-11 2023-12-01 中國大陸商迪哲(江蘇)醫藥有限公司 三唑并嘧啶化合物及其在治療癌症中之用途
CA3169667A1 (en) * 2020-02-28 2021-09-02 Dominic Reynolds Pyridazine derivatives for modulating nucleic acid splicing
WO2021236893A1 (en) * 2020-05-21 2021-11-25 Teon Therapeutics, Inc. Monocarboxylic acid transporter 4 (mct4) modulators and uses thereof
WO2021249969A1 (en) * 2020-06-10 2021-12-16 Merck Patent Gmbh Combination product for the treatment of cancer diseases
WO2022090527A1 (en) 2020-11-02 2022-05-05 Ares Trading S.A. Combination treatment of cancer
WO2022243574A1 (en) 2021-05-21 2022-11-24 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 3-(phthalazin-1-yl)benzenesulfonamide-based slc16a3 inhibitors and their therapeutic use
WO2022243573A1 (en) 2021-05-21 2022-11-24 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 1,2,4-triazolo[1,5-a]pyrimidine-based slc16a3 inhibitors and their therapeutic use
WO2025201236A1 (zh) * 2024-03-25 2025-10-02 北京福元医药股份有限公司 Mct4抑制剂及其药物组合物和用途
CN121735952B (zh) * 2026-02-26 2026-07-10 山东齐都药业有限公司 维立西呱的制备方法及其中间产物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072746A1 (en) * 2001-10-16 2004-04-15 Michael Sullivan Inhibitors of monocarboxylate transport
SE0300119D0 (sv) 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
DE102005034905A1 (de) 2005-07-26 2007-02-01 Federal-Mogul Nürnberg GmbH Verfahren zur Herstellung eines Kolbens für einen Verbrennungsmotor sowie Kolben für einen Verbrennungsmotor
WO2010089580A1 (en) 2009-02-06 2010-08-12 Astrazeneca Ab Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
WO2011114148A1 (en) * 2010-03-17 2011-09-22 Astrazeneca Ab 4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists
JP6612882B2 (ja) * 2015-01-22 2019-11-27 ザ スクリプス リサーチ インスティテュート プテリジンジオンモノカルボン酸トランスポータ阻害薬
WO2016118825A1 (en) * 2015-01-22 2016-07-28 The Scripps Research Institute Heterocyclic inhibitors of monocarboxylate transporters
AU2016277126A1 (en) * 2015-06-12 2017-12-14 Vettore, LLC MCT4 inhibitors for treating disease
US20190135747A1 (en) * 2016-05-12 2019-05-09 Regents Of The University Of Minnesota Indole and indazole cyanocinnamate compounds and therapeutic uses thereof
TWI823932B (zh) * 2018-05-11 2023-12-01 中國大陸商迪哲(江蘇)醫藥有限公司 三唑并嘧啶化合物及其在治療癌症中之用途

Also Published As

Publication number Publication date
DK3790879T3 (da) 2022-08-29
US12503473B2 (en) 2025-12-23
MX2020012058A (es) 2021-02-26
ZA202006971B (en) 2026-03-25
US11084827B2 (en) 2021-08-10
CN112469721A (zh) 2021-03-09
TW202015674A (zh) 2020-05-01
KR102863374B1 (ko) 2025-09-22
BR112020023068A2 (pt) 2021-02-09
KR20210013078A (ko) 2021-02-03
PT3790879T (pt) 2022-08-26
JP2021523177A (ja) 2021-09-02
CA3099579A1 (en) 2019-11-14
CN112469721B (zh) 2022-06-07
EP3790879B1 (en) 2022-06-29
US20210340150A1 (en) 2021-11-04
ES2927244T3 (es) 2022-11-03
AR115384A1 (es) 2021-01-13
CN115028637B (zh) 2024-03-22
JP7418353B2 (ja) 2024-01-19
EP3790879A1 (en) 2021-03-17
EP4134368A1 (en) 2023-02-15
US11851432B2 (en) 2023-12-26
CN115028636A (zh) 2022-09-09
AU2019264826B2 (en) 2024-05-23
US20210087196A1 (en) 2021-03-25
CN115028637A (zh) 2022-09-09
US20240217980A1 (en) 2024-07-04
WO2019215316A1 (en) 2019-11-14
TWI823932B (zh) 2023-12-01
AU2019264826A1 (en) 2020-11-26

Similar Documents

Publication Publication Date Title
MX2019012847A (es) Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer.
MX2020012058A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cancer.
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
DOP2019000168A (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
NI202000099A (es) Compuestos de purinona y su uso en el tratamiento del cáncer
CO2017002998A2 (es) Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1
MX2022011354A (es) Compuestos de pirimidina fusionados como moduladores de kcc2.
UY38625A (es) Compuestos y su uso en el tratamiento del cáncer
CO2017013708A2 (es) Macrociclos peptídicos contra acinetobacter baumannii.
MX2019004685A (es) Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3f] isoquinolina utiles en el tratamiento del cancer.
CU20170089A7 (es) Derivados de quinazolina utilizados para tratar el vih
AR093244A1 (es) Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2
MX2016015248A (es) Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal.
UY36145A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
CL2017000682A1 (es) Compuestos novedosos de imidazopiridazina y su uso.
PE20151607A1 (es) Formulaciones de compuestos organicos
BR112017009012A2 (pt) derivados de anel benzo de seis membros como inibidor de dpp-4 e seu uso
DOP2017000018A (es) [1,2,4]triazolo[4,3-b]piridazinas para su uso en el tratamiento de enfermedades proliferativas
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
CL2018000391A1 (es) Combinaciones farmacéuticas y su uso
ECSP18056196A (es) Derivados de indano

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20240522